backgroundth
mechan
immun
pathway
associ
chronic
rhinosinus
cr
fulli
understood
immunolog
chang
acut
exacerb
cr
may
provid
valuabl
clue
pathogenesi
perpetu
diseas
objectiveto
character
local
system
immun
respons
associ
acut
worsen
sinonas
symptom
exacerb
cr
nasal
polyp
crswnp
compar
control
methodsthi
nonintervent
prospect
studi
individu
crswnp
normal
control
subject
underw
baselin
visit
collect
nasal
secret
nasal
wash
serum
specimen
within
day
acut
worsen
sinonas
symptom
subject
underw
studi
visit
follow
postvisit
week
later
sinonas
outcom
score
immunolog
paramet
specimen
analyz
use
novel
unsupervis
learn
method
convent
univari
analysi
crswnp
patient
control
subject
show
signific
increas
score
acut
exacerb
increas
nasal
level
eosinophil
major
basic
protein
observ
crswnp
patient
network
analysi
serum
specimen
reveal
chang
set
immunolog
paramet
distinctli
associ
crswnp
control
particular
system
increas
vegf
gmcsf
level
notabl
valid
convent
analysi
conclusionscrswnp
patient
demonstr
distinct
immunolog
chang
local
system
acut
exacerb
growth
factor
vegf
gmcsf
may
involv
immunopathogenesi
subject
cr
nasal
polyp
experienc
exacerb
chronic
rhinosinus
cr
debilit
recalcitr
condit
secondari
persist
inflamm
sinonas
mucosa
result
symptom
nasal
congest
nasal
discharg
loss
smell
facial
pressur
mani
individu
cr
continu
suffer
lifelong
despit
aggress
manag
current
avail
treatment
pathogenesi
cr
poorli
understood
result
definit
cur
therapi
present
previou
crosssect
studi
cr
provid
valuabl
inform
character
differ
patient
control
establish
model
studi
pathophysiolog
cr
howev
current
key
molecul
play
pivot
role
diseas
incept
andor
progress
poorli
understood
one
way
address
major
gap
knowledg
may
studi
immunolog
chang
occur
acut
exacerb
chronic
diseas
previous
perform
pilot
studi
investig
immunolog
chang
diseas
exacerb
patient
cr
nasal
polyp
crswnp
preenrol
patient
ask
contact
studi
personnel
within
hour
worsen
respiratori
symptom
nasal
congest
drainag
sens
smell
collect
airway
specimen
found
protocol
feasibl
level
eosinophil
major
basic
protein
mbp
nasal
specimen
increas
acut
exacerb
diseas
current
studi
extend
selfreport
diseas
exacerb
model
explor
two
major
question
local
immunolog
respons
upper
respiratori
tract
acut
exacerb
differ
patient
crswnp
normal
control
uniqu
immunolog
respons
detect
serum
crswnp
exacerb
distinct
seen
normal
individu
order
extend
analysi
nasal
cytokin
signific
pilot
experi
addit
use
novel
network
graph
visual
method
obtain
highlevel
overview
pattern
cytokin
serum
perform
convent
analys
notabl
cytokin
adult
particip
year
recruit
allergyimmunolog
otolaryngolog
clinic
practic
two
academ
medic
center
mayo
clinic
minnesota
mayo
clinic
arizona
particip
recruit
start
fall
extend
spring
entir
studi
continu
june
inclus
criteria
along
subject
characterist
provid
tabl
crswnp
defin
presenc
cardin
symptom
chronic
rhinosinus
preced
month
includ
nasal
discharg
nasal
obstructioncongest
facial
painpressureful
decreas
smell
within
past
month
along
sinu
ct
scan
within
past
year
lundmackay
score
nasal
polyp
document
within
past
year
physic
exam
patient
crswnp
treat
topic
corticosteroid
patient
receiv
oral
glucocorticoid
past
month
exclud
studi
review
approv
irb
prior
initi
particip
provid
written
inform
consent
studi
nonintervent
prospect
design
fig
baselin
phase
time
enrol
visit
baselin
visit
particip
complet
sinonas
outcom
questionnair
demograph
factor
record
nasal
secret
serum
specimen
collect
store
frozen
two
addit
questionnair
obtain
baselin
phase
visit
exacerb
phase
particip
instruct
contact
studi
team
immedi
experienc
exacerb
natur
exacerb
defin
patientreport
worsen
sinonas
symptom
ie
runni
nose
nasal
congest
nasal
obstruct
day
particip
first
notic
exacerb
onset
upper
respiratori
symptom
denot
day
visit
ie
exacerb
visit
occur
within
day
day
resolut
phase
final
visit
visit
occur
approxim
day
day
score
nasal
secret
collect
visit
addit
serum
collect
visit
serum
specimen
collect
mayo
clinic
rochest
site
questionnair
complet
particip
base
recal
valid
larg
unit
kingdom
preand
postsurg
sampl
tool
compris
question
item
score
scale
scale
maximum
possibl
score
nasal
secret
collect
previous
describ
visit
briefli
nasal
secret
obtain
right
nasal
caviti
use
steril
sinu
secret
collector
xome
surgic
product
sampl
subject
uniform
protocol
extract
secret
mix
volum
steril
nacl
cocktail
proteas
inhibitor
thermo
scientif
ad
immedi
mucu
ratio
volum
weight
nasal
secret
collect
supernat
nasal
secret
collect
store
analys
see
onlin
repositori
inform
multiplex
data
serum
sampl
analyz
rang
oor
valu
less
limit
detect
assign
lower
limit
detect
assay
allow
simultan
comparison
unrel
biomark
express
valu
specif
biomark
normal
across
subject
normal
perform
use
follow
algorithm
v
norm
v
act
v
sd
v
norm
normal
valu
v
act
raw
valu
biomark
express
v
mean
raw
valu
sd
standard
deviat
across
subject
sinc
distanc
mean
neg
valu
minimum
v
norm
valu
biomark
scale
zero
remind
scale
measur
preserv
relationship
algorithm
preserv
proport
relationship
biomark
across
patient
allow
parallel
comparison
simultan
manner
differ
biomark
data
convert
format
suitabl
gener
network
layout
graph
gener
use
gephi
softwar
visual
analyz
network
graph
wwwgephiorg
graphic
represent
subject
biomark
denot
respect
node
subject
node
biomark
node
relationship
denot
link
line
connect
call
edg
transform
v
norm
valu
form
basi
edg
forcedirect
algorithm
forc
atla
pull
similar
node
togeth
push
dissimilar
node
apart
appli
reveal
emerg
associ
cluster
seen
network
corrobor
boundari
cluster
membership
defin
use
unsupervis
agglom
hierarch
cluster
node
size
set
rang
unit
prior
quantit
analysi
quantit
analysi
total
biomark
express
perform
use
weighteddegre
central
size
node
aggreg
connect
made
node
ie
number
connect
strength
connect
biolog
infer
molecular
cluster
discoveri
predict
function
partner
pathway
done
cytoscap
version
http
wwwcytoscapeorg
use
genemania
plugin
viral
detect
human
rhinovirusenteroviru
hrvev
perform
nasal
wash
visit
rtpcr
laboratori
dr
jame
gern
md
univers
wisconsinmadison
studi
sampl
size
determin
base
expect
chang
immunolog
paramet
pilot
studi
studi
sampl
calcul
base
hypothesi
increas
nasal
secret
exacerb
phase
crswnp
patient
compar
control
fifteen
total
subject
nine
subject
exacerb
would
allow
power
detect
differ
nasal
secret
level
group
chose
basi
sampl
size
base
evid
cytokin
initi
immun
respons
score
compar
visit
crswnp
normal
control
particip
well
crswnp
normal
control
particip
use
kruskalw
test
p
less
consid
signific
differ
signific
differ
two
proport
calcul
twotail
p
less
consid
signific
network
analysi
comparison
control
case
baselin
exacerb
done
use
unpair
pair
wilcoxonrank
test
p
less
consid
signific
twentytwo
control
twentythre
crswnp
particip
recruit
studi
nine
crswnp
particip
control
particip
acut
exacerb
onset
sinonas
symptom
studi
period
return
exacerb
phase
proport
control
crswnp
patient
experienc
exacerb
respect
tabl
describ
clinic
histori
demograph
particip
experienc
exacerb
particip
crswnp
group
older
gender
differ
group
crswnp
group
previou
surgeri
asthma
signific
differ
observ
rate
nasal
hrvev
detect
among
particip
exacerb
crswnp
patient
control
vs
crswnp
patient
control
mayo
clinic
rochest
site
assess
selfreport
measur
track
crswnp
symptom
compar
score
crswnp
control
group
baselin
visit
exacerb
visit
resolut
phase
visit
test
consist
selfreport
patient
done
measur
two
addit
time
baselin
score
consist
visit
crswnp
subject
significantli
higher
score
normal
control
p
fig
exacerb
score
increas
significantli
control
crswnp
group
ie
visit
vs
visit
p
chang
median
score
baselin
exacerb
exceed
threshold
signific
differ
tool
crswnp
control
group
score
visit
crswnp
normal
control
subject
show
signific
differ
control
crswnp
group
score
return
baselin
valu
resolut
phase
visit
thu
visit
score
reflect
clinic
exacerb
crswnp
case
control
natur
cours
ill
prior
observ
suggest
local
inflammatori
marker
mbp
elev
nasal
sampl
crswnp
case
exacerb
compar
baselin
investig
whether
chang
specif
crswnp
measur
select
cytokin
nasal
secret
crswnp
case
compar
normal
control
visit
baselin
nasal
level
significantli
elev
crswnp
case
compar
control
fig
differ
signific
mbp
case
control
fig
c
exacerb
howev
mbp
level
significantli
increas
crswnp
patient
compar
control
cytokin
includ
show
signific
differ
visit
exacerb
phase
crswnp
patient
control
analysi
specif
inflammatori
paramet
nasal
secret
confirm
enhanc
local
inflammatori
respons
crswnp
case
exacerb
sinc
examin
global
system
respons
comparison
local
nasal
immun
respons
offer
uniqu
insight
collect
local
specimen
practic
limit
collect
process
handl
next
focus
effort
biomark
analysi
serum
exacerb
phase
perform
multiplex
analysi
batteri
cytokin
biomark
analyz
data
use
multivari
network
visual
assess
associ
obtain
highlevel
overview
cytokin
pattern
sera
visit
visit
serum
specimen
patient
recruit
minnesota
site
use
analysi
initi
bipartit
network
depict
random
distribut
set
node
fig
set
white
node
subject
set
grey
node
cytokinesbiomark
subject
node
connect
biomark
node
edg
ie
line
forcedirect
algorithm
forc
atla
bring
similar
node
togeth
push
dissimilar
node
apart
weight
degre
central
appli
network
reveal
visual
associ
fig
edg
length
invers
proport
normal
biomark
express
ie
higher
valu
shorter
length
size
node
proport
aggreg
valu
connect
edg
ie
larger
subject
node
higher
aggreg
biomark
valu
compar
smaller
subject
node
network
topolog
exhibit
coreperipheri
layout
regard
larger
associ
node
center
smaller
less
dens
associ
node
peripheri
corrobor
pattern
seen
network
graph
defin
cluster
boundari
employ
independ
unsupervis
learn
method
agglom
hierarch
cluster
fig
rather
subject
defin
cluster
object
calcul
signific
break
dendrogram
use
join
distanc
function
measur
disjointed
p
use
object
approach
unsupervis
analysi
suggest
format
two
subject
cluster
four
biomark
cluster
fig
two
subject
cluster
reveal
signific
differ
membership
cluster
p
cluster
control
predomin
cluster
crswnp
predomin
fig
interestingli
analysi
also
reveal
presenc
three
crswnp
subject
controldomin
cluster
cluster
one
control
subject
casedomin
cluster
cluster
suggest
heterogen
within
subject
group
molecul
four
biomark
cluster
shown
figur
function
pathway
analysi
predict
model
involv
cluster
member
depict
supplementari
figur
cluster
enrich
biolog
function
cell
growth
proinflammatori
cytokin
cluster
b
enrich
cell
migrat
chemotaxi
biolog
function
cluster
c
suggest
cytokin
receptor
bind
respons
viru
respons
cluster
suggest
cytokin
regul
respons
sinc
layout
suggest
presenc
four
cluster
analyz
four
cluster
associ
closer
control
predomin
crswnp
predomin
cluster
use
aggreg
edg
weight
biomark
cluster
edg
subject
cluster
surrog
interclust
distanc
compar
degre
associ
subject
cluster
biomark
cluster
ad
controlpredomin
cluster
closer
biomark
cluster
b
biomark
cluster
wherea
proxim
specif
biomark
cluster
observ
crswnpdomin
cluster
fig
hand
subject
cluster
closer
ie
higher
edg
weight
valu
biomark
cluster
compar
cluster
suggest
crswnpdomin
cluster
gener
associ
strongli
measur
biomark
compar
controldomin
cluster
examin
molecul
express
network
compar
weighteddegre
central
wdc
biomark
node
aggreg
measur
number
strength
connect
made
node
seen
fig
biomark
belong
predominantli
two
biomark
cluster
b
greater
mean
wdc
egf
fgf
fractalkin
gmcsf
vegf
cluster
eotaxin
gro
pgdf
rant
cluster
b
form
core
network
contrast
one
molecul
cluster
c
mdc
repres
biomark
cluster
involv
thu
focus
next
analysi
candid
marker
examin
show
strongest
associ
crswnp
exacerb
compar
control
baselin
serum
cytokin
data
baselin
visit
transform
describ
materi
method
network
graph
gener
supplementari
figur
use
candid
marker
reveal
analysi
exacerb
network
assess
spatial
shift
associ
individu
cytokin
control
crswnp
exacerb
baselin
fig
amongst
candid
four
marker
fgf
gmcsf
fractalkin
vegf
cluster
significantli
closer
crswnp
visit
exacerb
compar
control
p
suggest
marker
strongli
associ
crswnp
exacerb
control
none
core
marker
show
signific
proxim
compar
control
final
confirm
result
network
analysi
compar
raw
untransform
serum
protein
concentr
valu
pgml
four
biomark
serum
concentr
fgf
fractalkin
vegf
gmcsf
significantli
higher
crswnp
patient
compar
control
exacerb
phase
p
fig
furthermor
crswnp
subject
serum
level
gmcsf
vegf
elev
crswnp
baselin
exacerb
phase
p
cr
recalcitr
diseas
associ
multipl
acut
exacerb
patient
lifetim
contribut
consider
morbid
constitut
major
burden
health
care
resourc
unlik
asthma
airway
challeng
exacerb
model
human
anim
provid
valuabl
inform
understand
pathophysiolog
diseas
trigger
cr
exacerb
fulli
understood
therefor
use
selfreport
acut
natur
exacerb
model
investig
mechan
immun
respons
cr
similar
compar
selfreport
model
use
success
asthma
studi
use
prospect
control
studi
design
detect
local
immun
respons
nasal
secret
distinguish
crswnp
patient
normal
control
acut
exacerb
data
extend
previou
find
crswnp
patient
verifi
mbp
elev
local
nasal
secret
crswnp
patient
exacerb
increas
level
crswnp
patient
baselin
may
reflect
dysregul
proinflammatori
innat
immun
increas
upon
exposur
incit
stimulu
viral
infect
potenti
role
pathway
crswnp
report
previous
investig
furthermor
increas
level
mbp
exacerb
may
point
involv
local
type
immun
respons
eosinophil
inflamm
result
also
consist
observ
previou
crosssect
studi
describ
potenti
role
eosinophil
crswnp
patient
us
altogeth
eosinophil
may
play
import
role
pathogenesi
crswnp
steadyst
condit
exacerb
diseas
studi
signific
differ
score
observ
baselin
exacerb
control
crswnp
patient
differ
greater
minimum
signific
differ
therefor
tool
may
suitabl
use
research
studi
employ
selfreport
natur
exacerb
hand
overal
score
differ
crswnp
patient
normal
control
exacerb
fig
suggest
tool
may
abl
discrimin
group
height
exacerb
questionnair
use
recent
measur
predict
outcom
cr
patient
includ
endoscop
sinu
surgeri
clinic
trial
surfact
corticosteroid
irrig
longterm
azithromycin
salin
irrig
current
studi
add
grow
bodi
literatur
support
use
questionnair
indic
diseas
exacerb
also
suggest
potenti
caution
interpret
data
normal
control
subject
experienc
acut
exacerb
upper
respiratori
symptom
nasal
sinu
sampl
extrem
import
understand
local
immun
respons
cr
serum
provid
supplementari
inform
serum
marker
use
easili
access
establish
noninvas
standard
collect
procedur
serum
specimen
near
homogen
inde
serum
biomark
periostin
use
recent
effort
predict
treatment
benefit
patient
asthma
furthermor
found
biomark
spectrum
nasal
secret
serum
ident
suggest
system
local
specimen
need
examin
effort
identifi
best
biomark
clinic
practic
research
undertook
method
screen
approach
use
network
visual
tool
studi
serum
paramet
cr
exacerb
biolog
paramet
analyz
preselect
variabl
base
pre
acquir
scientif
knowledg
use
method
aid
discoveri
pattern
larger
set
data
convent
analys
employ
measur
central
tendenc
median
mean
mode
limit
number
variabl
allow
organ
interpret
data
howev
process
may
compress
outlier
individu
variat
thu
potenti
risk
miss
import
clue
inform
contrast
unsupervis
simultan
variabl
analysi
method
allow
concurr
overview
high
number
variabl
without
compress
inform
particular
certain
novel
multivari
method
network
analysi
employ
unsupervis
learn
allow
data
reveal
pattern
without
priori
assumpt
compar
class
eg
case
control
lead
discoveri
associ
correl
without
preconceiv
distinct
potenti
advantag
employ
method
identifi
highlevel
pattern
initi
step
focus
substanti
use
convent
analys
therefor
studi
undertook
stepwis
approach
identifi
serum
biomark
associ
crswnp
exacerb
begin
analyt
identifi
highlevel
pattern
associ
cluster
focus
specif
marker
candid
marker
key
find
studi
distinct
biomark
signatur
vegf
gmcsf
detect
serum
specimen
crswnp
patient
natur
diseas
exacerb
focus
analysi
raw
protein
concentr
vegf
gmcsf
also
significantli
increas
exacerb
crswnp
compar
control
baselin
valu
local
product
vegf
gmcsf
polyp
tissu
document
previous
presenc
serum
may
import
marker
specif
exacerb
investig
necessari
examin
whether
detect
factor
blood
repres
spillov
local
product
outsidein
effect
judg
biolog
function
vegf
gmcsf
may
play
pivot
role
tissu
remodel
innat
adapt
immun
nasal
sinu
mucosa
respect
larger
studi
focus
molecul
necessari
investig
role
patholog
chang
crswnp
chronic
airway
diseas
sever
import
find
network
graph
merit
discuss
object
separ
studi
particip
cluster
exacerb
phase
reveal
crossov
subject
whose
biomark
signatur
mimick
cluster
mate
clinic
includ
opposit
group
thu
base
molecular
data
presenc
caselik
control
controllik
case
could
repres
heterogen
human
subject
differ
level
immun
dysregul
may
escal
acut
exacerb
inde
heterogen
regard
involv
differ
immunolog
pathway
differ
respons
like
exist
crswnp
patient
also
biomark
cluster
closer
crswnppredomin
cluster
controlpredomin
cluster
indic
elev
inflammatori
state
exacerb
crswnp
patient
limit
studi
first
sampl
size
small
power
calcul
base
pilot
studi
examin
chang
nasal
level
unexpectedli
found
statist
differ
level
crswnp
patient
control
subject
exacerb
possibl
reason
may
explain
find
time
specimen
collect
could
import
factor
sinc
releas
within
hour
anim
model
may
releas
acut
prior
patient
reach
clinic
sampl
collect
explan
may
includ
potenti
variabl
nasal
specimen
collect
techniqu
confound
treatment
effect
topic
corticosteroid
altern
may
key
factor
initi
inflamm
signific
proport
crswnp
patient
studi
similarli
immunolog
measur
neg
studi
share
possibl
risk
fals
neg
small
sampl
size
second
allow
treatment
intervent
per
usual
care
subject
studi
includ
continu
baselin
treatment
crswnp
group
topic
corticosteroid
could
influenc
natur
histori
diseas
exacerb
sever
strength
studi
first
studi
employ
prospect
design
crswnp
patient
includ
normal
control
group
demonstr
immun
signatur
increas
growth
factor
detect
system
uniqu
crswnp
patient
exacerb
regardless
natur
exacerb
trigger
allerg
versu
viral
infect
etc
suggest
prospect
selfreport
exacerb
model
may
provid
insight
underli
pathophysiolog
diseas
second
best
knowledg
first
applic
unsupervis
learn
model
clinic
studi
cr
show
may
feasibl
larger
studi
inde
power
network
analysi
may
lay
identif
cluster
biomark
patient
elucid
interact
moreov
studi
greater
number
subject
also
like
reveal
novel
immunolog
phenotyp
cr
specif
pathway
oper
subtyp
supposit
bring
us
closer
concept
person
medicin
cr
lead
appropri
costeffect
manag
common
vastli
heterogen
disord
nasal
level
mbp
visit
visit
acut
exacerb
nasal
secret
collect
exacerb
process
describ
method
section
concentr
inflammatori
marker
supernat
analyz
multiplex
assay
radioimmunoassay
data
present
median
horizont
bar
quartil
box
control
crswnp
unsupervis
network
analysi
patient
serum
biomark
exacerb
initi
bipartit
network
subject
white
node
biomark
gray
node
show
random
layout
subject
center
biomark
peripheri
panel
forcedirect
weight
degre
central
algorithm
appli
network
reveal
presenc
structur
visual
associ
node
panel
b
closer
node
repres
strongli
associ
node
node
size
set
associ
patient
cluster
biomark
cluster
acut
exacerb
present
panel
horizont
bar
box
vertic
line
median
quartil
rang
respect
aggreg
edgeweight
subject
cluster
biomark
cluster
comparison
made
controldomin
cluster
crswnpdomin
cluster
cluster
four
biomark
p
inter
cluster
comparison
per
patient
cluster
p
biomark
cluster
biomark
cluster
comparison
patient
cluster
panel
b
comparison
weight
degre
central
node
size
chang
associ
select
serum
biomark
subject
visit
exacerb
visit
edg
weight
serum
biomark
fgf
gmcsf
fractalkin
vegf
relat
control
crswnp
subject
calcul
visit
visit
data
present
median
horizont
bar
quartil
box
rang
vertic
line
edg
weight
valu
signific
differ
depict
horizont
line
serum
concentr
fgf
gmcsf
fractalkin
vegf
visit
visit
acut
exacerb
median
horizont
bar
quartil
box
rang
vertic
line
present
visit
subject
group
signific
differ
patient
group
visit
depict
horizont
line
divekar
et
al
clin
exp
allergi
author
manuscript
avail
pmc
june
